Member Info for NFTs

Karma

Well there you go add in the ones you vote at the AGM which will come later in the year and as NFX does it operates on empty empty.

The one benefit of main market is the Nomad and annual audit cannot force you to show funding for the year unlike AIM.

I would be more concerned about a virtual business with nothing but hopes that needs money.

Talking of signs mmmmmm

Ophidian

@Ophidian18

in amongst the carnage of after hours #AVCT - anyone else notice ? AVA6000 not being lined up for STS, AVA6000 is being lined up to REPLACE doxorubicin period !

Finally a strategy that looks like a proper Pharma company. Of course very likely to need a partner to do it

In the noise of rightfully disappointed shareholders on the placing that was clearly leaked causing a huge drop making the issuing price a joke!!

The RNS has all the good stuff in it so it won’t be here for long!

As explained

They will start process for orphan status it takes 3 months from the next available period to start the process.

It’s also never a guarantee process and therefore another risk as he explains majors are not really interested otherwise.

Why has it taken so long to figure such a basic thing out after so many experts hanging around?

If they don’t get it then what?

Is that game over?

When they get it they can then try again with potential partners and as mentioned this is 6 months plus so add that to 3 or 4 months and we are looking at best part of another year of outgoing costs. With no income.

They need to find funds tho cover this works and expenses plus general operating costs of listing filling etc. another 1/4 mil plus needed plus previous salaries and placing costs so 350 plus imo min.

If this is such a great product it should be child’s play to get.

Right you like pointing fingers and demanding investors answer.

Answer this one!!

Why has nobody even bothered to try buy this marvellous NXP002 yet after 5 years of knowing it works.

After knowing it can be used via inhale route which dramatically drops toxicity of Tranilast.

Why after two trials on humans lung tissue showing it has significant effects?

Yet it failed the duration test via rats which is a basic parameter of majors hence Anne Brindly wasting 1.5mil trying the rat route as that’s all she understands from her time at AZ etc.

So after all these experts looking under the bonnet what is it that they see that tells them it’s not worth it so we won’t bother buying it at few million?

Something isn’t right if that’s the case. If IPF is such a hard disease which it is to help and this clearly helps why can’t they stump up a few quid or even open a limited risk JV to help NFX?

Why?

Firstly it was an example of what you could expect and secondly I am fully aware of the limitations of main market as that’s been the main problem with this company unable to raise more than 10% of the agreed aggregate of allotted shares voted at the AGM so they need a separate vote to allow more. So that’s how they do it.

A lot of back payment in salaries to off the total ouch 😫

Well I was informed reduced and that’s still going to cost heavy WHEN FUNDS ALLOW!!!

Which oh dear me is coming oh yes it’s coming. Make sure you vote now.

They are taking salaries just reduced them to try hold back the raise till this new tax year when AGM takes place.

It just defers payment and they will probably make it up by giving themselves loads of options to help reduce the damage of dilution.

The problem is selling isn’t it as now you get locked for dilution and it will be significantly higher than before.

At 0.18p. Thats 277 million shares to raise £500,000 take of costs of placing etc.

Problem is now it will probably have to incur part loan notes part raise part warrants to existing shareholders etc

A messy affair.

But needs must.

So as mentioned they had less money than most suspected on last accounts as I did.

They got pennies from NXP001 as I suspected.

NXP004 again not worth much but makes people think it’s not a one trick pony to feed the market with bluff!!!

AstraZeneca as mentioned by someone last night is no stranger to NFX and they haven’t paid millions to get the product that essentially makes their own powder slightly less needed. Thats what NXP004 managed lol

NXP002 to be of interest to market needs Orphan status or the hard sell gets even harder. Takes 3 months and no guarantee for EU granting for that topographical area. I’d expect even more work for US Asia etc!! So loads of work and time costs money. Legals cost money. Salaries travel cost money. Listing costs money. Few patents securities expected also soon but these cost money.

So expect the bowl to be presented as advised last year but they managed a few K for NXP001 and research back pay has let them push it further but that’s risky gamble letting the coffers empty. Nothing new here it’s been running like that since the start.

Ultimately though now it’s a one chance to try get this higher up the food chain or it’s bargain basement for BP’s to pick up if they cannot manage it themselves.

Nobody in a rush obviously to come grab NXP002 even at this pitiful price.

If it was so good and majors such as AZ see that then simply why haven’t they said hey we see you struggling and massively cheap for an IPF combined therapy drug here is 10mil and we will get this going????

Why?

It’s been available now for years and they know exactly what they are looking at!

What is it they cannot see that NFX has known for the last 6 years?? And telling them??

Ha ha ha where’s that door lol 😝 as you all now realise what I have been warning you of for many months. No deal and cash required plus further work.

Money money money

All I read from that chat is money will be needed. Orphan status will take months and then months more to even get a negotiated deal etc. minimum a year before we see any potential deal and that’s only if they get orphan status otherwise it’s going to be even harder.

Big risks and little wonga. Better vote for that raise imo !!!!

Avacta as we know genuinely would like to list in the US.

I think the AIM knows this fact and doesn’t want Avcta to succeed due to it voicing it’s opinion about how the UK market is just not a place to build sustainable growth companies that go to become unicorns.

AVACTA is being punished in anyway possible by the market and it’s definitely time Alastair and his BOD stand up and pull the plug on the AIM or dual list over in the states driving the price this side.

It would be if a) He was CEO but he isn’t?

b) If they were close to signing anything tangible, but they are no way close to that.

C) Probably ok to holiday as this is only a virtual business and finance for the raise is probably ready subject to VWAP upon AGM period!

Make sure you have a few nuggets for the begging bowl there Redshoes!! CU there;)

Sorry yes I forgot Redshoes it’s tomorrow ✊

How’s Ebers getting on supposed to be real big lol 😂

Don’t tell anyone but Stephen Hawking is making a grand return tonight from his resting place to chat to any of the believers who want to pray 🙏 for him to find the elusive NXP002 formula. But it won’t help vertebra that’s been squashed falling down snow slopes.

Not a chance!!!

This company will not make enough to create enough cash to continue growth.

The figures are dropping when they were meant to be doubling year on year.

The model has had a decade to prove itself and it fails.

This will fail and any significant investor will ask the difficult questions from what’s evident here and either screw them down tight to take huge chunk of this company or walk away. So which will it be?

I’d definitely not be holding as I said the other day at 1.1p sell and wait till they complete funding as you will be able to buy much cheaper. Already saved you 50% or doubled your holding if daft enough to buy.